Astrogen Co Ltd. has disclosed prodrugs of 5-aminolevulinic acid (5-ALA) derivatives acting as fluorescence imaging agents and photosensitizers in photodynamic therapy with improved storage stability, reported to be useful for diagnosis and treatment of cancer, aging, alopecia, insomnia, inflammatory and metabolic disorders.
In a recently published study, researchers from Shandong Second Medical University and collaborators synthesized a new dual-gold(I) complex, named QB-1561, and tested its potential to inhibit drug-resistant cancer cells overexpressing ATP-binding cassette (ABC) transporters
Researchers from Universitatsklinikum Heidelberg presented data from a study that investigated the role of strawberry notch homolog 1 (SBNO1) in the development of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA).
Researchers from CJ Bioscience Inc. presented the discovery and preclinical characterization of CJRB-201, a novel microbiome-based therapy for the treatment of inflammatory bowel disease (IBD).
NLS Pharmaceutics Ltd., in collaboration with Aexon Labs Inc., has announced new preclinical findings on AEX-2, a non-sulfonamide dual orexin receptor agonist (DOXA) with potential for narcolepsy and related neurological disorders.
The FKBP5 gene encodes FKBP prolyl isomerase 5, a co-chaperone that modulates glucocorticoid signaling and that is expressed in T cells, neurons and in microglial cells in the central nervous system (CNS). The role of FKBP5 in the dysregulation of myeloid cells in the pathogenesis of multiple sclerosis was investigated in a murine model of experimental autoimmune encephalomyelitis.
A recent study by researchers from Nanyang Technological University identified Fanconi anemia complementation group M (FANCM) as a crucial regulator of alternative lengthening of telomere (ALT), aiming to develop new antisense oligonucleotides (ASOs) to suppress its function.
Family with sequence similarity 19 member A5 (FAM19A5) is a secretory protein highly expressed in the brain that regulates synapse dynamics through its interaction with leucine-rich repeat-containing 4B (LRRC4B). Noise exposure is one of the most significant causes of synapse loss between inner hair cells and auditory nerve fibers, leading to a decline in hearing sensitivity.
Researchers from Cedars-Sinai Medical Center presented the preclinical efficacy of KROS-401, an IL-4/IL-13 blocking peptide that effectively reprograms macrophages in glioma models.
Guangdong Fapon Biopharma Inc. has obtained IND clearance from the FDA for FP-008, its first-in-class immunocytokine for patients with solid tumors refractory to anti-PD-1 therapy.
RSS
